Vertex Pharmaceuticals (VRTX) Assets Average (2010 - 2026)
Vertex Pharmaceuticals' quarterly Assets Average came in at $26.1 billion in Q1 2026, up 14.78% year-on-year from $22.7 billion in Q1 2025, and up 3.21% quarter-over-quarter from $25.3 billion in Q4 2025.
Vertex Pharmaceuticals has reported Assets Average for 17 years, with the latest figure at $26.1 billion in Q1 2026.
- For the quarter ending Q1 2026, Assets Average rose 14.78% year-over-year to $26.1 billion; the trailing twelve-month figure through Mar 2026 stood at $26.1 billion (up 14.78% YoY), and the FY2025 full-year result was $24.1 billion, up 6.44% from the prior year.
- Assets Average for Q1 2026 stood at $26.1 billion, up from $25.3 billion in the prior quarter.
- The five-year high for Assets Average was $26.1 billion in Q1 2026, with the low at $13.8 billion in Q1 2022.
- Average Assets Average over 5 years is $20.9 billion, with a median of $22.0 billion recorded in 2024.
- Year-over-year, Assets Average surged 34.08% in 2023 and retreated 2.65% in 2025.
- Tracing VRTX's Assets Average over 5 years: stood at $17.4 billion in 2022, then advanced by 27.54% to $22.2 billion in 2023, then rose by 0.71% to $22.4 billion in 2024, then climbed by 12.8% to $25.3 billion in 2025, then increased by 3.21% to $26.1 billion in 2026.
- The last three Assets Average figures came in at $26.1 billion (Q1 2026), $25.3 billion (Q4 2025), and $24.4 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 13.04 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 33.42 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.72 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 331.70 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 40.89 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 26.06 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 26.03 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 40.71 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 5.05 Bn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | 2.30 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 26.06 Bn |
| Dec 31, 2025 | 25.25 Bn |
| Sep 30, 2025 | 24.45 Bn |
| Jun 30, 2025 | 23.46 Bn |
| Mar 31, 2025 | 22.71 Bn |
| Dec 31, 2024 | 22.39 Bn |
| Sep 30, 2024 | 21.19 Bn |
| Jun 30, 2024 | 22.02 Bn |
| Mar 31, 2024 | 23.32 Bn |
| Dec 31, 2023 | 22.23 Bn |
| Sep 30, 2023 | 21.04 Bn |
| Jun 30, 2023 | 19.66 Bn |
| Mar 31, 2023 | 18.56 Bn |
| Dec 31, 2022 | 17.43 Bn |
| Sep 30, 2022 | 16.14 Bn |
| Jun 30, 2022 | 14.92 Bn |
| Mar 31, 2022 | 13.84 Bn |
| Dec 31, 2021 | 13.03 Bn |
| Sep 30, 2021 | 12.42 Bn |
| Jun 30, 2021 | 12.17 Bn |
| Mar 31, 2021 | 11.93 Bn |
| Dec 31, 2020 | 11.53 Bn |
| Sep 30, 2020 | 10.76 Bn |
| Jun 30, 2020 | 9.55 Bn |
| Mar 31, 2020 | 8.61 Bn |
| Dec 31, 2019 | 7.92 Bn |
| Sep 30, 2019 | 7.27 Bn |
| Jun 30, 2019 | 6.79 Bn |
| Mar 31, 2019 | 6.39 Bn |
| Dec 31, 2018 | 5.43 Bn |
| Sep 30, 2018 | 4.48 Bn |
| Jun 30, 2018 | 4.14 Bn |
| Mar 31, 2018 | 3.75 Bn |
| Dec 31, 2017 | 3.37 Bn |
| Sep 30, 2017 | 3.24 Bn |
| Jun 30, 2017 | 3.12 Bn |
| Mar 31, 2017 | 2.92 Bn |
| Dec 31, 2016 | 2.75 Bn |
| Sep 30, 2016 | 2.58 Bn |
| Jun 30, 2016 | 2.52 Bn |
| Mar 31, 2016 | 2.49 Bn |
| Dec 31, 2015 | 2.47 Bn |
| Sep 30, 2015 | 2.40 Bn |
| Jun 30, 2015 | 2.27 Bn |
| Mar 31, 2015 | 2.25 Bn |
| Dec 31, 2014 | 2.37 Bn |
| Sep 30, 2014 | 2.26 Bn |
| Jun 30, 2014 | 2.16 Bn |
| Mar 31, 2014 | 2.26 Bn |
| Dec 31, 2013 | 2.45 Bn |
| Sep 30, 2013 | 2.58 Bn |
| Jun 30, 2013 | 2.49 Bn |
| Mar 31, 2013 | 2.58 Bn |
| Dec 31, 2012 | 2.74 Bn |
| Sep 30, 2012 | 2.66 Bn |
| Jun 30, 2012 | 2.48 Bn |
| Mar 31, 2012 | 2.28 Bn |
| Dec 31, 2011 | 2.15 Bn |
| Mar 31, 2011 | 1.63 Bn |
| Dec 31, 2010 | 1.81 Bn |
| Sep 30, 2010 | 1.77 Bn |
| Jun 30, 2010 | 1.71 Bn |
| Mar 31, 2010 | 1.86 Bn |